Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses

Combination Trial Aims To Improve Mortality Rate

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.  

Rio_de_Janeiro
Latin America has become the new epicenter of the pandemic, with deaths surging in Brazil, Peru, Chile, El Salvador, Guatemala and Nicaragua. A new study has warned that Brazil’s total death toll could rise five-fold to 125,000 by August, potentially exceeding the US.

Roche has begun a Phase III of its Actemra/RoActemra (tocilizumab) in combination with Gilead’s remdesivir as a potential treatment for hospitalized patients with severe COVID-19 pneumonia.

The combination trial is being launched in collaboration with Gilead Sciences Inc., and could help save lives of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip